{
  "docId": "019de073-3cb6-7521-8cc2-fe64231d84c9",
  "docSlug": "d538949ee3add2afed287b359e626655",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 25 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 25,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "Includes a timeline diagram of the study design and bulleted clinical outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/16",
  "deckHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9",
  "deckJsonHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json",
  "deckAnchorHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.69,
        "x": 0.273,
        "y": 0.815
      },
      "kind": "callout",
      "text": "500 mg once-daily dose achieved exposures suggesting high probability of PK/PD target attainment for treatment of MAC lung disease and was well-tolerated",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ce57df8-1fff-40ce-b3af-43c8c9659d4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.315,
        "w": 0.665,
        "x": 0.301,
        "y": 0.108
      },
      "kind": "diagram",
      "text": "Study design timeline showing Day 1, Treatment Period, EOT, and LFU",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b55fb0e-c8db-44f7-ab92-22608899dfa3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.66,
        "x": 0.301,
        "y": 0.665
      },
      "kind": "list",
      "text": "Data from EBO-101 and 6 other clinical studies combined into Population PK model; EBO-101 results used in combination with preclinical data to determine epetraborole oral dosage for Study EBO-301 Phase 2/3 pivotal trial",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a816733-2957-43e9-a212-ee4f92a847cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.55,
        "x": 0.301,
        "y": 0.458
      },
      "kind": "list",
      "text": "Epetraborole generally well-tolerated; No serious adverse events (SAEs), no severe AEs, no deaths; Linear PK",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a890c4b-69dc-48e2-9e02-8ea36c1f2a6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.69,
        "x": 0.273,
        "y": 0.625
      },
      "kind": "paragraph",
      "text": "Results support further clinical development of epetraborole in NTM lung disease",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b235980d-c76b-40ec-b3b9-805da7d62040",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.24,
        "x": 0.02,
        "y": 0.07
      },
      "kind": "title",
      "text": "EBO-101: A 28-Day Phase 1b dose-ranging study of oral epetraborole supports 500 mg once-daily dose for patients with treatment-refractory MAC lung disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09adaa91-7eaf-44f5-b037-65ce0c29a300",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.032,
        "w": 0.265,
        "x": 0.298,
        "y": 0.058
      },
      "kind": "title",
      "text": "Phase 1b Design and Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c97ca0fb-3197-439b-b224-5a30e0688168",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 14,
      "beatId": "679127e2-5c80-423c-8aa7-8057beadd113",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 14-17 present traction, including Epetraborole's improved antibacterial activity and favorable pharmacokinetics",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}